IMS Health (NYSE: RX) today announced an exclusive data and knowledge sharing agreement with the European Generic medicines Association (EGA) to advance the quality of healthcare decision-making by government and industry stakeholders. Under the agreement, IMS will provide the EGA with European generic drug sales information from its MIDAS database, which tracks 90 percent of prescription drugs in more than 80 countries. In addition, IMS will support the work of the EGA with expert opinion and consultative insights. IMS will be given access to EGA’s generic industry information and expertise, supporting and validating the company’s development of new offerings for the generic sector.
